Ferring Pharmaceuticals
Trial Pipeline
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
NCT06668493
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06510374
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06545955
Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy
NCT04113382
A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects
NCT05924321
Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)
NCT04163458
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)
NCT02522780
Efficacy and Safety of Prepopik® in Children for Overall Colon Cleansing in Preparation for Colonoscopy
NCT01928862
LutrePulse Hypogonadotropic Hypogonadism
NCT01976728
A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel
NCT01665599
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
NCT01552343
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
NCT01491971
A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator
NCT01464879
Menopur Mixed Protocol
NCT01417195
Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)
NCT01283022
Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery
NCT01127581
Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep
NCT01073930
Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy
NCT00925938
Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)
NCT00950105
Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor
NCT00828711
An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
NCT00615836
Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia
NCT00477490
A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding
NCT01280981
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
NCT00451958
Double-Blind,Randomized,Placebo-Controlled Efficacy & Safety Study of EUFLEXXA™ for Treatment of OA of the First CMC
NCT00423371
Efficacy and Safety Study of XP12B in Women With Menorrhagia
NCT00386308
Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor
NCT00308711
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 6 |
| Phase 3 | 15 |
| Phase 4 | 1 |
What the Pipeline for Ferring Pharmaceuticals Shows
According to the ClinicalTrials.gov registry, Ferring Pharmaceuticals is linked to 27 US clinical trials across every stage of research activity. Of those, 4 studies are currently recruiting — about 15% of the sponsor's indexed portfolio — and 23 are already marked complete, representing roughly 85% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Ferring Pharmaceuticals reports 16 late-stage studies (Phase 3 and Phase 4 combined) and 11 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Ferring Pharmaceuticals is Cervical Ripening with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.